Chr-A CRISPR Activation Plasmid (h): sc-400405-ACT
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- Chr-A CRISPR Activation Plasmid (h) is a synergistic activation mediator (SAM) transcription activation system designed to specifically upregulate gene expression
- Chr-A CRISPR Activation Plasmid (h) consists of three plasmids at a 1:1:1 mass ratio: a plasmid encoding the deactivated Cas9 (dCas9) nuclease (D10A and N863A) fused to the transactivation domain VP64, and a blasticidin resistance gene; a plasmid encoding the MS2-p65-HSF1 fusion protein, and a hygromycin resistance gene; a plasmid encoding a target-specific 20 nt guide RNA fused to two MS2 RNA aptamers, and a puromycin resistance gene
- The resulting SAM complex binds to a site-specific region approximately 200-250 nt upstream of the transcriptional start site and provides robust recruitment of transcription factors for highly efficient gene activation
- gRNAs encoded by Chr-A CRISPR Activation Plasmid (h) and Chr-A CRISPR Activation Plasmid (h2) target distinct regulatory regions upstream of the CHGA transcriptional start site. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: Chr-A Antibody (C-12): sc-393941
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Chr-A CRISPR Activation Plasmid (h) | sc-400405-ACT | 20 µg | $397.00 | |||
Chr-A CRISPR Activation Plasmid (h2) | sc-400405-ACT-2 | 20 µg | $397.00 |
CHGA encodes chromogranin A (Chr-A), a secretory granule protein enriched in neuroendocrine cells that supports dense-core vesicle biogenesis, peptide hormone storage, and regulated exocytosis. Proteolytic processing of Chr-A yields bioactive peptides that modulate neuroendocrine secretion, vascular and metabolic signaling, and stress-responsive pathways. CHGA expression tracks with neuroendocrine differentiation and secretory pathway activity, making it a useful marker and functional node for studies of endocrine signaling, vesicle trafficking, and peptide processing networks. Dysregulated CHGA/Chr-A levels and processing patterns are associated with neuroendocrine phenotypes and secretion-related disease biology, supporting its relevance in biomarker-oriented and mechanism-focused research.
Chr-A CRISPR Activation Plasmid (h) provides a targeted, non-destructive approach to upregulating endogenous CHGA expression without altering the underlying DNA sequence.
Chr-A CRISPR Activation Plasmid (h) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the CHGA locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.
Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the CHGA transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous Chr-A expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native CHGA locus and enabling the study of Chr-A-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of Chr-A pathway restoration in tumor cells with silenced or reduced CHGA expression.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.